drugset / Trial / NCT05437601

Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis

NCT05437601

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of astaxanthin in 80 moderate to severe knee osteoarthritis patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either astaxanthin 12 mg capsule daily or placebo capsule identical to astaxanthin daily for 8 weeks. Evaluation of pain, stiffness and improvement of physical function will be measured by WOMAC index before and after intervention. Inflammatory markers serum IL-6 and hsCRP will be measured before and after intervention. Astaxanthin related adverse events will be identified. Study outcome will establish safety and efficacy of astaxanthin in knee osteoarthritis.

Timeline

Start
2022-07-31
Primary completion
2022-12-19
Completion
2022-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Astaxanthin Small molecule 12 mg Oral

Indications